Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors
Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors
复制标题
DOI：
10.21037/apm-21-2023
复制
发表时间：
2021-09-24
影响因子：
--
通讯作者：
Liu, Li
中科院分区：
文献类型：
--
作者：
Xiao, Lu-Shan;Li, Qi-Mei;Liu, Li
背景：目前，一些癌症患者在接受免疫治疗后发生了超进展性疾病（HPD）。本研究采用实体瘤疗效评价标准1.1评价接受免疫检查点抑制剂（ICI）治疗原发性肝癌（PLC）患者的HPD发生率，并探讨HPD的危险因素。采用RECIST 1.1标准确定HPD患者。结果：在129例接受ICI治疗的PLC患者中，13例发生HPD，发生率为10.1%（13/129）。多因素回归分析显示淋巴结转移和肺转移是HPD的危险因素。包括淋巴结转移、肺转移、嗜中性粒细胞/淋巴细胞比值、白蛋白和体力状态的风险模型的曲线下面积为0.801（P
Background: At present, some cancer patients experience hyperprogressive disease (HPD) after receiving immunotherapy. This study used the Response Evaluation Criteria in Solid Tumors 1.1 to evaluate the incidence of HPD in patients receiving immune checkpoint inhibitors (ICIs) for treating primary liver cancer (PLC) and to explore the risk factors for HPD.Methods: This retrospective, single-center study included patients with PLC who were treated with ICIs. The RECIST 1.1 was used to determine patients with HPD. Univariate and multivariate regression analyses were performed to explore the risk factors for HPD, and clinical variables with prognostic significance for HPD were included to establish a risk model.Results: Among 129 patients with PLC treated with ICIs, HPD occurred in 13 patients (10.1%). In the multivariate regression analysis, lymph node metastasis and lung metastasis were risk factors for HPD. The area under the curve of the risk model, established by including lymph node metastasis, lung metastasis, neutrophil-lymphocyte ratio, albumin, and performance status, was 0.801 (P